A real-world observational study compared the cardiovascular outcomes of semaglutide and empagliflozin in adult patients with type 2 diabetes. The study found that semaglutide may be associated with a lower risk of stroke and showed greater weight loss and better glycemic control compared to empagliflozin, particularly in patients younger than 65 years and those with baseline HbA1c below 7%. Geographic differences were observed, with southwestern Pennsylvania showing the most evident benefit for semaglutide. However, the study has limitations due to its observational design and reliance on prescription records rather than confirmed medication use.

Source: Annals of Internal Medicine